Skip to main content
. Author manuscript; available in PMC: 2019 Nov 15.
Published in final edited form as: Int J Cardiol. 2018 Nov 15;271:312–316. doi: 10.1016/j.ijcard.2018.05.039

Table 1.

Baseline Clinical Characteristics of Fontan and Control Groups

Demographic variables Fontan (N=164) Control (N=82) p
Age, years 36 (25–43) 45 (35 – 52) <0.001
Male 88 (54%) 26 (32%) 0.01
Body mass index, kg/m2 27 ± 3 28 ± 6 0.12
Body surface area, m2 1.9 ± 03 1.9 ± 0.2 0.31
Laboratory data
Hemoglobin, g/dl 15.1 ± 0.4 13.3 ± 0.6 0.01
Albumin, g/dl 4.2 ± 0.4 4.4 ± 0.6 0.23
Creatinine, mg/dl 1.1 ± 0.4 0.9 ± 0.2 0.18
NT-pro BNP, pg/ml 191 (114 – 746) 47 (25 – 82) <0.001
Estimated plasma volume, ml 2971± 423 2703 ± 311 0.06
Medications
Diuretics 45 (27%) 14 (18%) 0.12
RAAS antagonist 46 (28%) 15 (19%) 0.13
Beta blockers 31 (20%) 20 (24%) 0.56
Comorbidities
Hypertension 1 (1%) 32 (39%) <0.001
Hyperlipidemia 42 (26%) 26 (32%) 0.21
Diabetes 14 (9%) 5 (6%) 0.41

NT-pro BNP: N-terminal pro-B-type natriuretic peptide; RAAS: Renin angiotensin aldosterone system antagonist